Abstract
Protection of the ischemic and reperfused myocardium represents a major therapeutic challenge.
Translating results from animal studies to the clinical setting has been disappointing, yet the need for effective intervention particularly to limit heart damage following infarction or surgical procedures such as coronary artery bypass grafting is substantial. Among the many compounds touted as cardioprotective agents is ginseng, a medicinal herb belonging to the genus Panax which has been used as a medicinal agent for thousands of years, particularly in Asian societies.
The biological actions of ginseng are very complex and reflect composition of many bioactive components although many of the biological and therapeutic effects of ginseng have been attributed to the presence of steroid-like saponins termed ginsenosides. Both ginseng as well as many ginsenosides have been shown to exert cardioprotective properties in experimental models.
There is also clinical evidence that traditional Chinese medications containing ginseng exert cardioprotective properties although such clinical evidence is less robust primarily owing to the paucity of large scale clinical trials. Here, we discuss the experimental and clinical evidence for ginseng, ginsenosides and ginseng-containing formulations as cardioprotective agents against ischemic and reperfusion injury. We further discuss potential mechanisms, particularly as these relate to antioxidant properties.
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Introduction
Research into cardiac protection has been, and continues to be one of the most, if not the most, active research areas in the cardiovascular field with thousands of papers published. The reason for such high research activity is not difficult to understand since reducing myocardial damage and infarct size following infarction is associated with improved long-term prognosis and reduced risk for the subsequent development of heart failure. Research spanning nearly four decades and encompassing various experimental models (see below) has identified a large number of both pharmacological and non-pharmacological approaches to limit cardiac muscle damage, indeed with a great deal of efficiency at least as seen in experimental studies. Table 1 presents a very limited list of interventions that have shown promise over the years as potentially effective cardioprotective strategies. Unfortunately, robust experimental data have not translated into clinical efficacy, which has recently been referred to as a "remarkable record of failure" Ginseng has been used as a therapeutic agent for a large number of medical disorders for thousands of years, particularly in Asian societies. Ginseng is a complex natural compound belonging to genus Panax, family Araliaceae, represented by various species and containing many bioactive constituents such as the steroid-like saponins named ginsenosides which are thought to be largely but not exclusively responsible for ginseng's therapeutic properties.
Although it is beyond the scope of this review to discuss the general chemical and biochemical properties and characteristics of ginseng species, a number of reviews dealing with these issues can be recommended (Lü et al. 2009; Yamasaki 2000; Yuan et al. 2010; Qi et al. 2011 ). D r a f t
| P a g e
Moreover, a recent review focuses on the chemistry, structure, nomenclature and therapeutic properties of individual ginsenosides (Kim et al. 2017) . We have recently reviewed in this Journal the potential benefits of ginseng and ginseng-related products to limit myocardial remodelling and heart failure (Karmazyn and Gan 2017). Here, we focus on another potential benefit of ginseng and assess the evidence regarding the direct cardioprotective effects of ginseng, ginsenosides and ginseng-containing products against ischemia and reperfusion induced myocardial injury from both experimental and clinical studies. To fully appreciate the bases for this it is important to understand the experimental models which have been used to identify potentially effective cardioprotective agents as discussed in the following section.
Experimental models to identify cardioprotective agents
Both in vivo and in vitro techniques have been used extensively in the search for identifying potentially effective cardioprotective strategies. The latter are basically the simplest approaches in which isolated cardiomyocytes or cardiac tissues are subjected to ischemic and reperfusion conditions generally by treating these preparations with hypoxic and then oxygenated media with various compositions. As reviewed by Yellon and Hausenloy (2007) , the reperfusion component is of paramount importance in view of the well-established concept that reperfusion of the ischemic heart represents an exacerbation and acceleration of already-existing ischemic induced injury. This so-called reperfusion injury has substantial clinical relevance since myocardial reperfusion with various means such as using thrombolytic agents, angioplasty or surgical revascularization represents a critical treatment of patients who have suffered a myocardial infarction (Bassand et al. 2005) . Interestingly though, the nature of reperfusion injury appears to be quite distinct from injury observed during the initial ischemic insult and protecting the reperfused heart has also materialized into a major clinical challenge (Yellon and Hausenloy D r a f t 5 | P a g e 2007). Ideally, an effective cardioprotective agent is one which attenuates myocardial injury when administered at the time of reperfusion. Certainly, such treatments would have major clinical usefulness since they can potentially be administered to patients following infarction.
Thus, limitation of reperfusion injury represents an important therapeutic target. However, limiting ischemic injury, that is injury occurring prior to reperfusion is also of benefit particularly under circumstances such as coronary artery bypass surgery when effective cardioprotective agents can be administered prior to the surgical procedure therefore protecting the heart during induced ischemia (Mentzer Jr 2011) . A summary of the phases of injury occurring during myocardial ischemia and reperfusion is illustrated in Figure 1 in relation to the key role of sodium-hydrogen exchange isoform 1 (NHE-1). Activation of NHE-1 can lead to intracellular calcium overload through the sodium-calcium exchanger (NCX) resulting in activation of processes that result in apoptotic or necrotic cell death. Thus, timely early reperfusion before the onset of these processes can prevent cell death concomitant with functional recovery (reversible ischemia).
In vitro models
The use of isolated cells and tissues ex vivo presents several advantages as these models preclude the possible contribution of neuronal and hormonal factors to the injury process thus simplifying the model and providing a better opportunity to study intrinsic mechanisms mediating injury (Maddaford et al. 1999) . However, such approaches are also potentially limited in terms of physiological and clinical relevance since they do not represent ischemia and reperfusion per se but rather conditions associated with ischemia and reperfusion such as hypoxia and reoxygenation. Nonetheless, Portal et al. (2013) have recently shown that freshly isolated mouse D r a f t 6 | P a g e cardiomyocytes can exhibit a similar profile of injury when subjected to hypoxia and reoxygenation as that seen under in vivo conditions. More clinically relevant ex vivo models are the isolated freshly perfused heart, the so called Langendorff preparation (Döring 1990) or the Neely working heart (Neely et al. 1967) which are perfused through the coronary arteries, either retrogradely or antegradely respectively, with either simple saline buffers or complex media and which can then be subjected to actual ischemia and reperfusion using various techniques. Even though these experimental models have provided a plethora of valuable information, as with most ex vivo preparations results obtained using these techniques should be interpreted with caution primarily as these preparations are generally devoid of hormonal or neuronal influence or indeed influence by other critical blood-borne factors (Hearse and Sutherland 2000) .
In vivo models
As reviewed by Black (2000) cardioprotective strategies can also be studied and assessed using in vivo live animal models. In most cases this involves subjecting animals to coronary artery ligation with reperfusion and determining the modulation of infarct sizes by treatment. Several animal species have been studied using this approach although rats and dogs predominate as animals of choice to determine infarct sizes in vivo. However, with the development of genetic mouse models of heart disease there has been increasing interest in the use of the coronary artery ligation infarction model in this species (Gao et al. 2010) . Experimental coronary artery ligation offers an additional advantage as infarct sizes can be readily manipulated simply by altering the duration of the coronary artery ligation period. Moreover, as a general rule the degree of reperfusion injury, that is injury occurring after restoration of coronary flow, is dependent on the duration and therefore the severity of the preceding ischemic period (Figure 1 ). D r a f t 7 | P a g e As summarized in Table 1 , studies using such diverse experimental models have revealed a plethora of experimental approaches including pharmacological agents as well as procedures such as ischemic preconditioning (brief sub-lethal cycles of ischemia prior to prolonged ischemia) and postconditioning (brief cycles of ischemia following prolonged ischemia and before reperfusion) as effective cardioprotective strategies experimentally but these have generally proved disappointing when applied to patients. One of the potential reasons for this is the fact that most experimental animal studies may be poorly applicable to the human population as the former generally employed young animals with no co-existing morbidities, in contrast to what is seen with cardiac patients who are generally in the older age bracket and who often present with other clinical conditions with both factors potentially confounding effective cardioprotection. Another basis for disappointing translational results may lie with the fact that mechanisms of ischemia-and reperfusion-induced cardiac injury are distinct as well as complex.
Thus, focussing on the best appropriate target(s) as well as ideal timing of treatment are likely of paramount importance. With respect to the latter this represents a major challenge as administering a cardioprotective strategy after infarction, that is at the time of reperfusion, may have limited value in view of the fact that substantial cell death has already occurred prior to initiation of treatment (Schaper and Schaper 1988) . Limiting damage, particularly that produced by reperfusion may therefore represent a challenging goal in the setting of acute myocardial infarction. As alluded to above, a clinical scenario where cardiac protection efficacy could be tested under more controlled environment is in high risk patients undergoing coronary artery bypass grafting (CABG) since in these patients treatment can be initiated during ischemia (i.e. cardiac arrest during surgery) as well as reperfusion following completion of the surgical procedure (Mentzer Jr 2011) . Cardioprotection was indeed observed in high risk CABG patients D r a f t 8 | P a g e who were administered the NHE-1 inhibitor cariporide although any potential clinical development of this agent was negated by the unexpected increased occurrence of cerebrovascular thromboembolic events (Mentzer et al. 2008) .
Mechanisms of injury
A complicating factor in designing effective cardioprotective strategies likely also reflects the complexity of mechanisms underlying injury and cell death. From a general perspective cell death can occur from both necrosis as well as apoptosis, also referred to as "programmed cell death" with each mode of death reflecting distinct mechanisms of injury (Fink and Cookson 2005) . Although they share some common mechanisms, cardiac injury and cell death occurring as a consequence of ischemia are quite different and distinct from reperfusion injury occurring following post-infarction restoration of blood flow. Although it is beyond the scope of this review to discuss the underlying complex mechanisms of ischemia-and reperfusion-induced injury in substantial detail various excellent reviews can be recommended (Binder et al. 2015; Yellon and Hausenloy 2007; Mentzer Jr 2011; Hausenloy and Yellon 2015) . Briefly, it is appropriate to state that defective intracellular ion regulation especially that occurring during prolonged ischemia is a prerequisite for irreversible ischemic injury, intracellular calcium dysregulation as evidenced by elevations in intracellular calcium levels represents a major contributor to this process (Opie 1991) . Thus, as illustrated in Figure 1 , a major goal of mitigating ischemic-induced injury involves the inhibition of intracellular calcium overload and preventing the transition from reversible to irreversible injury (Opie 1991) . While reperfusioninduced injury also reflects complex intracellular events, a major contributing factor to this type of injury is the rapid reintroduction of oxygen upon early reflow thus leading to the generation of reactive oxygen species (ROS) resulting in myocyte injury (Maddika et al. 2009 ; D r a f t 9 | P a g e Braunersreuther and Jaquet 2012). Therefore, inhibitors of ROS generation as well as free radical scavengers have generally proven effective in experimental models of reperfusion injury, both in vitro and in vivo. The beneficial consequences of inhibiting ROS generation and attenuating intracellular calcium dyshomeostasis are multifold although one of the major consequences which can greatly attenuate the degree of injury is inhibition of the mitochondrial permeability transition pore (mPTP) in the inner mitochondrial membrane whose activation results in subsequent loss of ionic homeostasis, matrix swelling, outer membrane rupture and the development of apoptosis (Javadov and Karmazyn 2007) . Indeed, as will be evident below, inhibition of oxidative stress as well as intracellular calcium abnormalities appear to be some of the primary mechanism underlying the cardioprotective effects of ginseng-related compounds.
Although marked ischemia-and reperfusion-induced injury can be achieved using in vitro preparations, it should be noted that mechanisms contributing to such injuries are markedly more complex in vivo. This is principally due to the fact that extracardiac factors contribute to myocardial injury as well. A primary example of this, as demonstrated many years ago, would be the accumulation and infiltration of neutrophils in the ischemic area which can then release a myriad of cardiotoxic compounds such as ROS and other pro-inflammatory mediators (Williams 1996; Jordan et al. 1999) . Indeed, inhibition of neutrophil accumulation and function represents an effective cardioprotective strategy in the experimental setting.
Assessment of injury and cardioprotective efficacy
As will be evident when describing individual examples below, there are a number of determinations one can undertake to assess the degree of injury using the various experimental models that have been referred to. For example, the degree of cardiomyocyte injury can be D r a f t 10 | P a g e determined indirectly by assessing the release of enzymes such as creatine kinase (CK) or lactate dehydrogenase (LDH) as well as Troponin I which can then be measured either in the bloodstream for in vivo studies or in superfusion or perfusion media for ex vivo models of ischemia-and reperfusion-induced injury (Singh et al. 2010) . Moreover, injury can be assessed histologically to directly determine the degree of damage or by cell viability assays, the latter of particular usefulness when using myocyte preparations. These approaches do not effectively differentiate between necrotic or apoptotic cell death which have substantially different characteristics and which contribute in their individual ways to mediate myocardial injury (Kajstura et al. 1996) . A large number of assays are available which can measure apoptosis by determining the levels of specific enzymes and factors which are involved in the apoptotic process as well as apoptosis-specific injury including DNA fragmentation as determined by TdTmediated dUTP-biotin nick end-labeling (TUNEL) staining (Darzynkiewicz et al. 2008 ). Cardiac function is also of substantial benefit as an index of degree of injury or protection by interventions particularly when using experiments involving intact heart preparation either in vivo or in isolated tissues.
Evidence for ginseng, ginsenosides and ginseng-related products as cardioprotective agents Ginseng species
The potential cardioprotective properties of ginseng have been known for at least two decades with the finding that Trilinolein, a triacyglycerol purified from P pseudoginseng, an atypical member of the Panax species, protected the isolated rat heart against ischemia, an effect which was associated with preserved mitochondrial structure, a benefit attributed to antioxidant D r a f t 11 | P a g e properties of this compound as well as maintenance of membrane fluidity and inhibition of calcium influx (Chan et al. 1996 (Chan et al. , 1997 .
Thus, the antioxidant properties of ginseng and its ginsenosides appear to be an important factor in mediating their cardioprotective actions. This has been demonstrated directly in myocytes exposed to a free radical generating system to generate the superoxide anion or by the addition of exogenous ROS and where cell death under these conditions was markedly reduced by berry extracts of P quinquefolius or North American ginseng (Shao et al. 2004; Mehendale et al. 2005) .
Interestingly, in one of these studies (Shao et al. 2004 ) the efficacy of the P quinquefolius berry extract was greater than that seen with extract taken from the ginseng root, suggesting that the former has a greater antioxidant property. It has also been reported (Sui et al. 2001 ) that P quinquefolius leaf extracts, specifically 20s-protopanaxdiol saponins, reduce infarct size through an antioxidant mechanism in dogs subjected to acute myocardial infarction (Sui et al. 2001 ).
However, numerous other targets may also be involved such as reduction in endoplasmic reticulum stress as shown for P quinquefolius which was associated with reduced apoptosis (Xue et al. 2013; Liu et al. 2013 Liu et al. , 2015 , inhibition of platelet aggregation either when tested alone or in combination with established antiplatelet agents as well as the regulation of a large number of genes and proteins involved in numerous aspects of myocardial homeostasis as has been proposed for P notoginseng as well as ginseng-containing formulations (Yue et al. 2012; Zhu et al. 2013 ). Moreover, P notoginseng has been shown to enhance mobilization of C-kit + bone mesenchymal stem cells in rats subjected to myocardial infarction thus potentially enhancing post-infarction myocardial repair ) as well as to reduce oxidative stress and inflammation (Han et al. 2013) . P ginseng, also referred to as Asian ginseng, has also been shown to reduced infarct size in a rat infarction model D r a f t 12 | P a g e through a mechanism involving preservation of PI3K and serine/threonine protein kinase Akt (protein kinase B) levels in the myocardium which are important components of the so-called myocardial salvage pathway (PI3K-Akt) resulting in increased NO production via eNOS activation thus representing a potential additional important target site for ginseng-related protection (Pei et al. 2013; Zhou et al. 2011) . Interestingly, as discussed below, activation of this pathway has been proposed as a mechanism of action for various individual ginsenosides. Guo et al. (2009, 2010) have proposed an antioxidant effect of P notoginseng in a rat acute myocardial infarction model which could be due to decreased cytokine production. Lim et al. (2013 Lim et al. ( , 2014 have reported that Korean red ginseng (P ginseng subjected to a heating process) administration exerts cardioprotective effects against isoproterenol-induced injury as well as electrophysiological changes in rats in the absence of any changes in heart rate thus implicating a direct cardioprotective effect. In these studies, it was proposed that the salutary effect of Korean red ginseng was due primarily to an antioxidant effect similar to that seen in studies using ischemia models of injury.
The salutary effect of ginseng has also been found to occur in older animals, a potentially important finding as virtually all studies assessing cardioprotection have been carried out using young subjects. For example, Luo et al (2015) have shown that administering a P ginseng extract for 90 days to aged (18 months old) rats prior to induction of acute coronary artery ligation and reperfusion reduced infarct size, indices of apoptosis, and improved left ventricular function and survival. Several mechanisms were proposed for this protection including the stimulation of the salvage pathway, referred to above as well as two sirtuin isofoms (Sirt1 and Sirt3) which are known to play important roles in cell homeostasis leading overall to reduced apoptosis (Luo et al. 2015) .
D r a f t 13 | P a g e A summary of the cardioprotective effects of different ginseng species as well as ginsenosides, compound k and ginseng-containing formulations which are discussed in the following sections is presented in Table 2 .
Ginsenosides
Both total saponin extracts as well as individual ginsenosides have been shown to exert cardioprotective effects. For example, cardioprotection has been documented with individual ginsenosides such as ginsenoside Re which attenuated hydrogen peroxide-induced toxicity in chick cardiomyocytes thus demonstrating an antioxidant property (Xie et al. 2006) . However, other mechanisms may also be at play with this particular ginsenoside such as enhancing endothelial nitric production by activating eNOS: it has been shown that this effect is associated with cardiac potassium channel activation thus mitigating ischemia-reperfusion injury (Furukawa et al. 2006) . It is interesting that in this study it was shown that ginsenoside Re releases NO via a nongenomic pathway involving sex steroid receptor activation resulting in potassium channel activation in cardiac myocytes (Furukawa et al. 2006) . Indeed, ginsenoside Re has been shown to exert several electrophysiological effects on the cardiac cell conducive to cardiac protection in addition to targeting potassium channels including the inhibition of calcium channels, also via increased NO generation (Bai et al. 2003 (Bai et al. , 2004 . In addition, various groups (Wang et al. 2009a; Yin et al. 2005; Xu et al. 2013 ) have reported that P quinquefolius saponin extracts produce a reduction in cardiac injury including an attenuation of apoptosis by directly modifying apoptosisregulating factors, improving function and decreasing oxidative stress in both myocytes as well as hearts subjected to coronary artery ligation. As noted above, a potential mechanism may also involve the inhibition of mPTP opening. Thus, administering a P quinquefolius saponin extract for four weeks to rats prior to ischemia and reperfusion produced a significant reduction in D r a f t 14 | P a g e infarct size associated with mitochondrial protection likely associated with inhibition of mPTP opening (Li et al. 2014) . These saponins have also been proposed to exert beneficial effects in infarcted rat hearts by promoting coronary angiogenesis through the upregulation of expression of proangiogenic growth factors (Wang et al. 2007 ), an effect similarly observed for saponin extracts from the flower buds of P notoginseng (Yang et al. 2016) .
Several other ginsenosides have also been shown to exert protective effects through a number of (2015) showed that Rg1 also improved cardiac function in rats subjected to infarction in which Rg1 was co-administered with salvianolic acid B, extracted from the herb Salvia miltiorrhiza, although no benefit was seen in ginsenoside Rb1 treated animals. However, the lack of benefit seen with ginsenoside Rb1is in contrast with other studies showing robust cardioprotection with Rb1 treatment. Indeed, it is interesting that a single intravenous administration of Rb1 ten minutes before subjecting rats to 45 minutes of coronary artery occlusion and two hours reperfusion reduced cardiac injury suggesting a preconditioning-like effect of this ginsenoside (Wang et al. 2008 ). The benefit exerted by Rb1 was associated with increased Akt (protein kinase B) phosphorylation, which as already noted is an important component of the so-called myocardial salvage pathway (PI3K-Akt). Moreover, Wang et al. (2008) have reported that Rb1-mediated protection was abolished by wortmannin, a non-specific PI3K inhibitor. Generally similar effects were seen in ischemic D r a f t 15 | P a g e and reperfused hearts from diabetic rats treated with Rb1 ) an effect which may also involve increased production of endothelial-dependent NO via eNOS upregulation . Improved cardioprotection for both ginsenoside Rb1 and Rg1 was shown to occur when the ginsenosides were administered to rats within core-shell liposomal vehicles in order to improve bioavailability . In that study improved protection was seen in both a cerebral model of ischemia and reperfusion as well as myocardial ischemia produced by administering the pituitary gland extract pituitrin, which consists primarily of vasopressin and oxytocin ). It appears that Rb1 exerts cardioprotective effects through a plethora of mechanisms. For example, in addition to the various mechanisms just noted, ginsenoside Rb1 has recently been proposed to protect the heart by inhibiting succinate accumulation in both ischemic and reperfused working rat hearts as well as hypoxic and reoxygenated cardiomyocytes (Li et al. 2017b ). This resulted in improved activity of pyruvate dehydrogenase through inhibition of succinate-associated HIF-1α activation and GPR91 signaling resulting in attenuated cardiac acidification, improved mitochondrial dysfunction and reduced apoptosis (Li et al. 2017b) . Cui et al. (2017) also showed that Rb1 exerted several salutary effects in rats subjected to 30 minutes coronary artery ligation followed by 90 minutes of reperfusion including reduced infarct size, apoptosis and improving cardiac function. These effects were attributed to an ability of Rb1 to directly inhibit RhoA thus preventing RhoAdependent cell signalling and improving ATP preservation. Interestingly, an identical mechanism has been proposed for the cardioprotective effects of ginsenoside Rg1 when administered to rats subjected to 30 minutes of coronary artery occlusion followed by 90 minutes of reperfusion (Li et al. 2018 ). It is interesting that in a study using a metabonomic approach, a combination of the ginsenosides Rg1 and Rb1 failed to substantially improve myocardial metabolic status when administered to rats for seven days following induction of myocardial infarction (Jiang et al. 2014 ). However, marked improvement was seen when these ginsenosides were administered in combination with other purported bioactive compounds found in the Chinese Traditional Medicine Sheng-Mai San including schizandrin and ophiopogonin D (Jiang et al. 2014) . While the finding of lack of efficacy of the ginsenosides was surprising, the study nonetheless reinforces the concept that ideal cardioprotective benefit of ginseng will likely be particularly evident when used as adjunctive therapy with other medications.
There is good evidence that in vivo treatment with ginseng-related compounds bestows subsequent protection ex vivo. For example, administering either total or purified (panaxadiol or panaxatriol) saponins to rats for seven days resulted in subsequent protection of excised isolated D r a f t perfused hearts which were then subjected to ischemia and reperfusion as demonstrated by improved function, attenuation of cell damage concomitant with a reduction in oxidative stress, the latter proposed as the primary basis for the salutary effects of these compounds (Kim and Lee 2010; Aravinthan et al. 2015) . Han et al. (2013) showed a similar beneficial effect in rats subjected to coronary artery occlusion and reperfusion that were administered P notoginseng.
This study also showed that the benefit could be enhanced with coadministration of extracts of the Safflower plant (Cartharmus tinctorius L) thus suggesting that combination therapy could effectively enhance the cardioprotective effect of ginseng-related compounds. Furthermore, seven-day pretreatment with a saponin extract from P japonicas exerted substantial protection in rats subjected to 12 hours of coronary artery ligation, without reperfusion, as manifested by improved function, reduced injury including apoptosis as well as reduced markers of oxidative stress and expression levels of cytokines (He et al. 2012; Wei et al. 2014) .
It is clear from the evidence that there is substantial variability in terms of efficacy of various ginsenosides as cardioprotective factors. Such variability may reflect the experimental model used or, as recently proposed, the chemical structure of the ginsenoside species. With respect to the latter Feng et al. (2017) recently suggested that compounds lacking the hydroxide group at C6 may be more effective, at least in terms of reducing apoptosis in H9c2 cells (a cardiomyoblast cell line) subjected to hypoxia and reoxygenation although it remains to be determined whether this concept can be applied to other experimental models.
Thus, when taken together it appears that ginsenosides exert salutary effects through multiple mechanisms although many of these ginsenosides share the ability to activate the PI3K-Akt pathway resulting in increased NO production secondary to eNOS activation. How this specifically occurs is not known although as proposed in Figure 2 , one possible mechanism may D r a f t 18 | P a g e involve the stimulation of receptor tyrosine kinase (RTK) by individual ginsenosides which results in eNOS activation secondary to stimulation of protein kinase Akt (Fulton et al. 1999; Liu et al. 2014) . This hypothesis needs to be assessed with further studies particularly since various ginsenosides such as Rg3 may activate a number of cell signalling pathways which result in eNOS upregulation (Hien et al. 2010 ).
Compound K: a bioactive ginsenoside metabolite
The ginseng metabolite compound
formed via biotransformation of a number of ginsenosides by intestinal bacteria, also exerts cardioprotective properties. Tsutsumi and coworkers showed that compound K administration to mice reduced infarct size and calcium-induced mitochondrial swelling following ischemia and reperfusion in vivo which was associated with enhanced Akt and eNOS activities as discussed above for ginsenoside Rb1 (Tsutsumi et al. 2011) . These findings further implicate the involvement of the PI3K-Akt myocardial salvage pathway as a potential key target for the cardioprotective effects of numerous ginseng-related products.
Ginsenoside-containing preparations
Complex preparations containing ginsenosides have also been studied as cardioprotective agents, many of which are in common use for the treatment of coronary heart disease in Asian countries (Hung et al. 2015) . One of these herbal medications, Shenfu, is currently used in Asian societies, particularly China, as treatment for cardiovascular diseases as well as other conditions. Wang et al. (2009b) have reported that Shenfu reduces apoptosis in cardiomyocytes exposed to hypoxia and reoxygenation, an effect which was associated with increased expression of the antiapoptotic protein B-cell lymphoma 2 (Bcl-2) and a concomitant decrease in pro-apoptotic caspase-3 D r a f t 19 | P a g e activation. Shenfu has also been shown to reduce infarct size when administered to rats prior to induction of myocardial infarction produced by coronary artery ligation followed by reperfusion likely due to antioxidant effects of the formulation (Zheng et al. 2004 ).
Another similar formulation, Sheng-mei-san, consisting of Radax ginseng plus other constituents including Fructus schisandrea has been studied for its cardioprotective properties. Li et al. (1996) have postulated that the presence of lignan-enriched extract of Fructus schisandrae accounts for the beneficial effects of Sheng-Mai-San although others have implicated the ginsenoside content of this formulation as a basis for cardioprotection, at least in a mouse model of isoproterenol-induced cardiac injury ). Sheng-Mai-San has also been shown to reduce infarct size in rabbits when administered up to three days prior to infarction, with no benefit observed with acute treatment . The benefit was proposed to be mediated by activation of protein kinase C and opening of mitochondrial ATP-sensitive potassium channels primarily attributable to the presence of ginsenosides and lignans as the primary active ingredients in this formulation . Zhao et al. (2016) have reported that a Sheng-mai-san derived product, YiXin-Shu, specifically developed for the treatment of ischemic heart disease, attenuates myocardial ischemic and reperfusion injury in hypercholesterolemic mice through a mechanism involving inhibition of myocardial apoptosis by blunting mitochondrial mediated pro-apoptosis pathways, reduction in oxidative stress as well as by upregulating the nuclear LXRα receptor.
Administering the herbal preparation Danshen, containing notoginseng has also been shown to exert numerous protective effects in rats subjected to acute coronary artery ligation and reperfusion (Ren-an et al. 2014) . As for several other ginseng-related products this protection was associated with activation of the Akt myocardial salvage pathway (Ren-an et al. 2014 ).
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Clinical evidence for cardioprotection
As is the case for most areas of ginseng research related to cardiovascular therapeutics, there is a paucity of strong translational evidence demonstrating clinical benefit. In the case of cardioprotection there is some evidence for benefit seen in patients undergoing reperfusion with either thrombolytic therapy (Guo and Zhang 2001) or percutaneous coronary intervention (PCI/angioplasty) (Geng et al. 2004 ) as demonstrated by reduced injury and improved function in those patients receiving Shenmai. In fact, a meta-analysis of clinical studies in which Shenmai was administered to patients following myocardial infarction showed some benefit in terms of reduced mortality, development of heart failure, circulatory shock and re-infarction (Hu et al. 2012 ). However, as pointed out by the authors themselves these analyses have serious limitations in view of the small sample size in individual trials and thus should be interpreted cautiously (Hu et al. 2012) . In a small study, patients undergoing PCI and receiving Traditional 
Conclusion and future directions
There is a substantial amount of unequivocal experimental data supporting the concept of a cardioprotective effect of ginseng and ginseng-containing products (summarized in Table 2 ). As is the case for many naturally-derived products and ginseng in particular, robust clinical evidence for the use of ginseng products for protecting the ischemic myocardium is generally lacking in Chan, P., Niu, C.S., Cheng, J.T., Tsao, C.W., Tsai, S.K., and Hong, C.Y. 1996. Trilinolein preserves mitochondria ultrastructure in isolated rat heart subjected to global ischemia through antioxidant activity as measured by chemiluminescence. Pharmacology 52: 216-225.
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